The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma.
This article describes the development of SPE and HPLC methods for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. Several extraction and HPLC methods have been described previously for the determination of each of these analytes in plasma separately. The simultaneous determination of these analytes is important for the routine monitoring of diabetic patients who take combination medications and for studying the pharmacokinetics of the combined dosage forms. In addition this developed method can serve as a standard method for the plasma determination of these analytes therefore saving time, effort and money. The recoveries of the developed methods were found to be between 76.3% and 101.9%. The limits of quantification were between 5 and 22.5 ng/ml. The intraday and interday precision (measured by coefficient of variation, CV%) was always less than 9%. The accuracy (measured by relative error %) was always less than 12%. Stability analysis showed that all analytes are stable for at least 3 months when stored at -70 degrees C.
Aburuz
S
S
Department of Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan. aburuz@ju.edu.jo
Millership
J
J
McElnay
J
J
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005907:Gliclazide / Q000097:blood*; D005913:Glipizide / Q000097:blood*; D005905:Glyburide / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000097:blood*; D008687:Metformin / Q000097:blood*; D012015:Reference Standards; D012680:Sensitivity and Specificity
D007004:Hypoglycemic Agents; D008687:Metformin; D005907:Gliclazide; D005905:Glyburide; D005913:Glipizide